New this week:
- Portfolio checks. Paste the molecules you hold and QOPE checks each one against FDA protection, approved generic filings, real NADAC generic pricing, shortage status and Medicare Part B spend, then ranks them by how soon each loses its price. These checks now live in Radar.
- Price Erosion Atlas. The Drug Profile now charts how generic entry eroded prices for comparable launches, so you can benchmark an upcoming loss of exclusivity against real history.
- Part B buy-and-bill tab. Physician-administered drugs get a dedicated Medicare Part B view on the Drug Profile.
- Honest freshness stamps. Every table now shows the actual last-refreshed date reported by the data pipeline for that dataset.